2
We are the right partner forall kind of transactions in the Pharma / Healthcare Industry
Partnering• Licensing out (worldwide)• Licensing in (worldwide)• Supply & distribution agreements• Business planning
Product Transactions(asset deals)• Divestments of products /
brands / portfolios • Acquisitions of products /
brands / portfolios
Mergers &Acquisitions (share deals)• Divestments and acquisitions of
companies • Specialization in divestment of
production sites• Strategic alliances (joint ventures) Core
Business Areas
StrategicConsulting• Valuation for financial institutions• Portfolio management• Marketing & sales strategies• Change management• Executive Search• Post Merger Integration
3
Why we arethe right partner for you!
5 STEPSTO SUCCESS
1
5
4
2
Expertise25 years in-depth expertise in all aspects of Pharma M&A, Product transactions, Partnering and Strategic consulting
AdvisorsFully involved Senior Advisors with executive management expertise in the pharmaceutical industry
SuccessTarget oriented, efficient, intelligent and successful project managementMore than 500 transactions closed
GlobalUnique global database and comprehensive network of healthcare and M&A experts
ExperienceBroad experience in cross-border-transactions worldwide
1
5
2
4
33
1
5
4
3
2
Our team
Managing PartnerKLAUS MANLIK
PrincipalMICHAEL COMPANIE
Senior DirectorMATHIAS KÄSEBIER
Portfolio Analyst / ConsultantULRIKE DÄXL
Long term expertise in numerous national and international projects.
Specialist in M&A and product transfers.Broad marketing & sales and business development experience in leading positions in big pharma and medium-sized enterprises.
In-depth experience in the pharmaceutical industry.
Specialist in international M&A project management.
Specialization in the divestment and acquisition of products and brands.
Long term experience in operative and strategic business development. Specialist in M&A and product divestiture processes and growth strategies.Previous industry experience especially in OTC/Wellness/Phyto included:CEO of Heel Inc., Albuquerque, USA. Director of Consumer Health Americas, Boehringer Ingelheim, International Marketing Director Natural Health.
Expert knowledge of general and comparative financial analysis. Specialist in establishing growth strategies, e.g. creating shareholder value. Previous industry experience as Senior Portfolio Manager/ Analyst for healthcare stocks (pharma, medtech & biotech) in several asset management companies, including in-depth analysis and stock picking strategies.
5
Dr. Renate Moser – Regional Associate Austria, Wien (Austria)Thomas Merrifield – Territorial Associate North America incl. Canada, South CarolinaDr. Kah Foo – Territorial Associate Asia (incl. SEA,, Japan, Korea), SingaporeVolker Adam – Regional Associate Mexico, Mexico City (Mexico)
Our international team
Lukas Radtke – Regional Associate Brazil and Mercosur, Sao Paulo (Brazil)
Arun Kumbhat – Territorial Associate IndiaPablo Faglioli – Territorial Associate ArgentinaDr. Diether Wienbeck – Territorial Associate CEE, Russia, CIS
Headquarter – Germany, Starnberg
Yornick Hurtado – Territorial Associate Central America and Venezuela, Miami (USA)
6
Rx
Generics
OTC
Pharmaceuticalproduction
Biotech
Hospitals
Nutraceuticals
Dermacosmetics
Diagnostics
Medtech
R&D Licensing Projects
Veterinary
OUR KNOW-HOW
7
Our Services forMergers & Acquisitions, Product Transactions and Partnering
Market Intelligence
Strategic Planning
Project Management
Valuation of Business
Fact Sheet / Info Memo
Identification of Candidates
Due Diligence Guidance
Face-to-face meetings
Negotiations
Post Merger Integration
Post Transaction Implementation
Process Monitoring
8
Strategy analysis Strategy developement Strategy planning Implementation Monitoring
Strategic Consultingwith a broad range of services to meet strategic challenges
Organizational change
Company strategy
Sales strategy
Portfolio management
Valuation of business opportunities
Marketing strategy
ALL OVER THE WORLD22.000 companies and 50.000 individuals
10
Proprietary global databaseBANNERT MANLIK’s unique proprietary global database includes more than 22,000 companies and more
than 50,000 individuals, which guarantees fast-paced and success-oriented project management
43% Europe, incl. Germany & CEE30% Central & South America9% USA5% Asia
8% Russia3% Mena2% ROW
11
Contact data of key persons, e.g. management and BD
Successor regulations
Openness to cooperation, joint ventures, acquisitions, etc.
R&D pipeline
Current status and future strategic directions
Financial details
Company coordinates
Classification of production facilities by pharmaceutical forms, packaging materials, etc.
Business areas: ethical drugs, generics, food supplements, etc.
Market segments: Rx, OTC, OTx, Medtech, etc.
Therapeutic areas, further classified by ATC Code
Company type: Pharma, Biotech, PE Start-up, CMO, CRO etc.
Proprietary global databaseAll information has been collected and developed over the last 25 years
Publ
ic in
form
atio
n
Priv
ate
info
rmat
ion
12
Proprietary global databasePrecise and quick customized targeting to identify and match potential candidates
Final Candidates
Core List Candidates:
Short-list Candidates:
Long-list Candidates:
Universe
Potential candidates after analysis
confirmed indication of interest
Indication of interest after teaser
2-3
5
25-30
60-80
100 %All relevant preliminary candidates
13
A selection of successfully completed projects
14
Our referencesIn more than twenty-five years of business, BANNERT MANLIK has successfully conducted more than
500 national and international transactions, ranging from 1m to 100m USD (sales value)
Our Office
Bannert Manlik Consultants GmbHMaximilianstrasse 4e 82319 Starnberg, Germany
www.bannert-manlik.com
Tel: +49 8151 973 65 0 Fax: +49 8151 973 65 25
About Bannert Manlik Consultants
Since 1991, BANNERT MANLIK is one of the leading international strategic consulting firms for the pharmaceutical and healthcare industries.
We assist our clients throughout the entire M&A process, provide portfolio management strategies, as well as support in the realization of international growth and other strategic goals.